North Texas Research Forum 2025 Files Download Full Text (492 KB) Division North Texas Hospital Medical City Arlington Specialty Obstetrics & Gynecology Document Type Poster Publication Date 2025 Keywords non-arteriticanterior ischemic optic neuropathy, semaglutide, type 2 diabetes, weight loss, GLP-1RA Disciplines Internal Medicine | Medicine and Health Sciences | Obstetrics and Gynecology Abstract Background: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-RA), was introduced and approved by the United States Food and Drug Administration (FDA) for the management of type 2 diabetes in 2017
The concentration may differ from the label
Immune Resilience: Offers wellness insights associated with normal immune function and overall vitality
They synthesized the results from 24 different clinical trials to see if melatonin truly works (Choi et al., 2022)
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008;32(1-2):1-15.]
Clinical evidence demonstrates that semaglutide combined with lifestyle modifications produces sustained weight loss and improves cardiometabolic markers in the majority of users
)
